Keenova Therapeutics Q3 sales jump 32% to $549.5M
Key points
- Keenova Therapeutics reported third-quarter 2026 net sales of $549.5 million from continuing operations, up 32% year-over-year, supported by Acthar Gel and XIAFLEX.
- The continuing-operations loss narrowed to $96.1 million from $242 million, while adjusted EBITDA reached $233 million.
- Keenova raised its full-year pro forma sales outlook to $2.00 billion–$2.025 billion and expects approximately $110 million in pre-tax merger synergies during 2026.
Keenova Therapeutics (NYSE:MNK) reported third-quarter 2026 net sales of $549.5 million from continuing operations, up 32% year-over-year, and raised its full-year financial outlook.
Growth included a full quarter of XIAFLEX sales, compared with two months of contributions in the prior-year period, alongside increased sales of Acthar Gel.
Acthar Gel generated $226.5 million in revenue, up 25% year-over-year, while XIAFLEX contributed $163.7 million during the quarter.
The continuing-operations loss narrowed to $96.1 million from $242 million, while adjusted EBITDA reached $233 million, with results also including a $151 million pre-tax loss from the Percocet divestiture.
The company expects approximately $110 million in pre-tax merger synergies during 2026 and is advancing additional XIAFLEX applications, including a supplemental FDA filing for plantar fibromatosis targeted for the first quarter of 2027.
Keenova raised its full-year 2026 pro forma sales forecast to $2.00 billion–$2.025 billion and adjusted EBITDA guidance to $750 million–$770 million, while Phase 3 hammer toe study enrollment, which began in August 2026, continues
